Median OS 36.2mo in INSPIRE-LM is striking: 30 pts w/ HER2+ breast LM treated w/ IT trastuzumab + pertuzumab. 29/30 also had WBRT or proton CSI. Single-arm study. Encouraging, but we can't separate the contributions of RT and IT therapy. #ESMO26 #radonc https://t.co/Ik5n6h9DZS https://t.co/yHENYHJAnr